American Society of Clinical Oncology (ASCO)

Journal of Clinical Oncology (JCO) Podcast

Health EN ↓ 462 episodes

The Journal of Clinical Oncology Podcast presents analyses and discussions centered on the latest findings published in ASCO's flagship Journal of Clinical Oncology. Host Dr. Davide Soldato facilitates interviews and scholarly discourse on the most impactful published findings. The Journal of Clinical Oncology Podcast is the trusted resource that empowers you to integrate cutting-edge evidence into clinical practice. The year's fellows interview authors and summarize the top Journal of Clinical Oncology articles in the series, JCO Article Insights.

Author

American Society of Clinical Oncology (ASCO)

Category

Health

Podcast website

sites.libsyn.com

Latest episode

Jun 11, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 5M+ downloads · 4.8 rating iOS soon

Episodes

Phase 2 Study of Multi-Cancer Detection from Breath Samples 11.06.2026

Guests Akash Kulgod and Dr. Sanjeev Kulgod and host Dr.  Davide Soldato discuss JCO article, " Canine Olfaction Combined with Bayesian Modeling for Multi Cancer Detection from Breath Samples, a Phase 2 Study in India " and the innovative breath-based canine olfaction for multi-cancer detection in low-resource settings, the Bayesian modeling integration, and future prospects for scalable, non-invas...

JCO at ASCO 2026: Individualized Neoantigen Therapy Plus Pembrolizumab in Melanoma 01.06.2026

JCO Editorial Fellow Dr. Ash Gurumurthi and JCO Associate Editor Dr. Grant McArthur discuss the ASCO 2026 Simultaneous Publication paper " Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase 2b KEYNOTE-942 Study ." LINK TO FULL TRANSCRIPT

JCO at ASCO 2026: Pemigatinib Phase 3 FIGHT-302 Trial in Cholangiocarcinoma 01.06.2026

JCO Podcast host Dr. Davide Soldato and  JCO Associate Editor Dr. Dr. Eileen M. O'Reilly discuss the ASCO 2026 Simultaneous Publication paper " Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase 3 FIGHT-302 Trial ." LINK TO FULL TRANSCRIPT

JCO at ASCO 2026: Individual Patient Pooled Analysis of Low-Dose Tamoxifen in DCIS 31.05.2026

JCO Editorial Fellow Dr. Yuvanesh Vedaraju and  JCO Associate Editor Dr. Kathy Miller discuss the ASCO 2026 Simultaneous Publication paper " Low-Dose Tamoxifen in Non-Invasive Breast Neoplasia: Long-Term Results from an Individual Participant Data Pooled Analysis ." LINK TO FULL TRANSCRIPT  

JCO at ASCO 2026: Neoadjuvant Sacituzumab in MIBC 31.05.2026

JCO Editorial Fellow Dr. Jake New and  JCO Associate Editor Dr. Umang Swami discuss the ASCO 2026 Simultaneous Publication paper " Neoadjuvant Sacituzumab Govitecan in Patients with Muscle-Invasive Bladder Cancer: Primary Results of SURE-01 Trial ." LINK TO FULL TRANSCRIPT

JCO at ASCO 2026: Intravesical Recombinant BCG with Chemo-Immunotherapy in MIBC 29.05.2026

JCO Editorial Fellow Dr. Jake New and  JCO Associate Editor Dr. Andrea Necchi discuss the ASCO 2026 Simultaneous Publication paper " Addition of Intravesical Recombinant BCG to Perioperative Chemo-Immunotherapy in Muscle-Invasive Bladder Cancer: Primary Analysis of the Single Arm Phase 2 Trial SAKK 06/19 ." LINK TO FULL TRANSCRIPT    

Adjuvant Durvalumab and the Future of Early-Stage NSCLC 14.05.2026

Guest Dr. Glenwood Goss and host Dr. Davide Soldato discuss JCO article, " Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer " and the implications of minimal residual disease,  results regarding the efficacy of immunotherapy in the adjuvant setting, and the evolving strategies for patient care in lung cancer treatment. LINK TO FULL TRANSCRIPT

JCO Article Insights: LEAP-010 Study in Recurrent/Metastatic Head and Neck Cancer 27.04.2026

Host Jake New summarizes and offers insights into the JCO article by Licitra et al., "Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study." LINK TO FULL TRANSCRIPT

Infections in Two Diet Strategies in HSCT and Leukemia Patients 09.04.2026

Guest Dr. John Wingard and host Dr. Davide Soldato discuss JCO article, " Randomized Non-inferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem Cell Transplant and Acute Leukemia Patients ," the reason behind the trial, its design, methodology, results, and the implications for future dietary approaches in hematology. LINK TO FULL TRANSCRIPT

JCO Article Insights: ctDNA in DLBCL - Ready for Prime Time? 30.03.2026

In this episode of JCO Article Insights, host Dr.  Ash Gurumurthi summarizes JCO articles, " Phased Variant–Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study " and " Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma " TRANSCRIPT Ash...

The CISTO Study: Radical Cystectomy or Bladder-Sparing Therapy for Recurrent NMIBC 12.03.2026

Guest Dr. John Gore and host Dr. Davide Soldato discuss JCO article, " 12-Month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent Non-Muscle Invasive Bladder Cancer ," which compares radical cystectomy and bladder sparing therapy for patients with recurrent high-grade non-muscle invasive bladder cancer. Dr. Gore and Dr. Soldato focus on the stud...

JCO Article Insights: Atezolizumab, Bevacizumab, and Non-Platinum Chemotherapy for PROC 23.02.2026

In this episode of JCO Article Insights, host Dr. Melis Canturk summarizes the article, " Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial, " by Harter et al. TRANSCRIPT Melis Canturk: Hello, and welcome to the JCO Article Insight . I'm your host, Melis Canturk, and today we w...

JCO Article Insights: Ribociclib Plus Letrozole in Recurrent LGSOC: GOG 3026 23.02.2026

In this episode of JCO Article Insights, host Dr. Melis Canturk summarizes the article, " Phase 2 Trial of Ribociclib plus Letrozole in Women with Recurrent Low-Grade Serous Cancer of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial, " by Slomovitz et al.  TRANSCRIPT Melis Canturk: Hello, and welcome to JCO Article Insights . I'm your host, Melis Canturk, and today we will be discuss...

NCI Working Group on Biochemically Recurrent Prostate Cancer 12.02.2026

Host Dr. Davide Soldato and guests Dr. David Einstein and Dr. Ravi Madan discuss JCO article, " National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations ," underscoring the need for a consensus on clinical trial designs implementing novel endpoints in this population and the importance of PSA doubling time as a prognostic factor, wi...

Association Between EOL SACT and Healthcare Utilization 08.01.2026

Host Dr. Davide Soldato and guests Dr. Kerin Adelson and Dr. Maureen Canavan discuss JCO article " Association Between Systemic Anticancer Therapy Administration Near the End of Life with Health Care and Hospice Utilization in Older Adults: A SEER Medicare Analysis of End-of-Life Care Quality ," highlighting adverse outcomes for patients who receive any type of systemic anticancer therapy(SACT) at...

Milan Consensus Endpoints for Bladder Preservation in MIBC 11.12.2025

Guests Dr. Andrea Necchi, Dr. Ashish Kamat and host Dr. Davide Soldato discuss JCO article " End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer ," focusing on the evolving treatment landscape of MIBC (muscle-invasive bladder cancer) and the need to properly design novel trials investigating non-operative management while includi...

JCO at 2025 ASH: Pirtobrutinib in Untreated CLL 09.12.2025

JCO Editor-in-Chief Dr. Jonathan Friedberg is joined by colleagues Dr. Jennifer Woyach, Dr. Wojciech Jurczak, and Dr. Matthew Davids to discuss simultaneous publications presented at ASH 2025 on pertibrutinib, a new upfront treatment option for patients with chronic lymphocytic leukemia. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Jonathan Friedberg: I...

JCO at ASH 2025: A New Validated Staging System for AL Amyloidosis: AL-ISS 07.12.2025

JCO Editorial Fellow Peter Li and author Dr. Jahanzaib Khwaja discuss the  ASH 2025 Simultaneous Publication article, " A New Validated Staging System for AL Amyloidosis With Stage lllC Defining Ultra-Poor Risk: AL International Staging System ." TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Peter Li : Welcome to this episode of JCO Article Insights . I...

JCO Article Insights: Simultaneous Durvalumab and CRT in Unresectable Stage III NSCLC 24.11.2025

In this episode of JCO Article Insights, host Dr. Ece Cali Daylan interviews author Dr. Jeffrey Bradley about the article, " Simultaneous Durvalumab and Chemoradiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer " by Bradley, et al published October 13, 2025. TRANSCRIPT Dr. Ece Cali: Welcome to this episode of JCO Article Insights . This is Dr. Ece Cali, JCO Editorial Fellow. Today I'm...

Health Outcomes in Older Childhood Cancer Survivors 20.11.2025

Guest Dr. Rusha Bhandari and host Dr. Davide Soldato discuss JCO article "Health Outcomes Beyond Age 50 Years in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study, " with a particular focus on mortality data, development of secondary malignancies and the importance of education for both patients and healthcare providers regarding long-term follow-up and care. TRANSCR...

Long-Term Remission After Cilta-cel in Patients With RRMM 13.11.2025

Guest Dr. Sundar Jagannath and host Dr. Davide Soldato discuss JCO article " Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma ," and the efficacy of CAR-T cell therapy in patients with heavily pretreated RRMM (relapsed/refractory multiple myeloma). TRANSCRIPT Dr. Davide Soldato: Hello and wel...

JCO Article Insights: Xevinapant Plus Chemoradiotherapy in Unresected LA SCCHN 27.10.2025

In this episode of JCO Article Insights, host Dr. Lauren Shih summarizes the article, " Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study " by Bourhis, et al published September 03, 2025 TRANSCRIPT  

Income Among Adolescents and Young Adults Surviving Cancer 09.10.2025

Host Dr. Shannon Westin and guest Dr. Giancarlo Di Guiseppe discuss the JCO article " Long-Term Dynamic Financial Impacts Among Adolescents and Young Adults With Cancer: A Longitudinal Matched-Cohort Study " TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Dr. Shannon Westin: Hi everybody and welcome to another episode of JCO After Hours , the podcast where we go in dept...

JCO Article Insights: Phase I DLL3/CD3 T-Cell Engager in DLL3-Positive SCLC or NECs 29.09.2025

In this JCO Article Insights episode, Dr. Ece Cal interviews Dr. Martin Wermke, author of the JCO article, " Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas ." TRANSCRIP T The disclosures for guests on this podcast can be found in the transcript....

TTFields in Locally Advanced Pancreatic Adenocarcinoma 11.09.2025

Host Dr. Shannon Westin and guest Dr. Hani Babiker discuss the JCO article " Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study. " TRANSCRIPT TTFields in Locally Advanced Pancreatic Adenocarcinoma Dr. Shannon Westin: Hello everyone, and welcome to another episode of JCO After Hours , the...

Listen to the Journal of Clinical Oncology (JCO) Podcast podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.